What Happens When You Microdose Ozempic? A Clinical Look at Sub-Therapeutic Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing Ozempic (typically 0.05 to 0.15 mg weekly, below the FDA-approved 0.25 mg starting dose) reduces gastrointestinal side effects in 60 to 70% of patients but delays weight loss by an average of 4 to 6 weeks compared to standard titration
• The body's GLP-1 receptor occupancy at microdoses is partial, meaning you get appetite suppression without full gastric emptying delay, which is why nausea drops but so does early weight loss velocity
• Microdosing is not an FDA-approved protocol and is only available through compounded semaglutide, not through brand-name Ozempic pens which start at 0.25 mg
• Most patients who microdose successfully transition to standard doses within 8 to 12 weeks, but 15 to 20% remain on below-label doses long-term due to persistent side effect sensitivity

Direct answer (40-60 words)

When you microdose Ozempic below the standard 0.25 mg starting dose, you experience reduced nausea and gastrointestinal side effects but slower initial weight loss. Your body gets partial GLP-1 receptor activation, enough for mild appetite suppression but not the full metabolic effect. Most patients use microdosing as a temporary bridge to standard dosing.

Table of contents

1. What "microdosing" means in the context of semaglutide
2. The pharmacology of sub-therapeutic GLP-1 dosing
3. What most articles get wrong about microdosing Ozempic
4. Clinical effects comparison: microdose vs. standard dose
5. The FormBlends microdose titration pattern
6. Side effect reduction at microdoses: what the data shows
7. Weight loss outcomes: how much slower is microdosing?
8. When microdosing makes clinical sense (and when it doesn't)
9. How to microdose compounded semaglutide safely
10. The transition from microdose to therapeutic dose
11. Long-term outcomes for patients who start with microdosing
12. FAQ

What "microdosing" means in the context of semaglutide

In GLP-1 therapy, "microdosing" refers to starting below the FDA-approved initial dose. For semaglutide (the active ingredient in Ozempic and Wegovy), the approved starting dose is 0.25 mg once weekly for four weeks. Microdosing typically means 0.05 mg, 0.10 mg, or 0.15 mg weekly.

The term borrowed from psychedelic therapy, where microdosing means taking sub-perceptual doses to avoid acute effects while maintaining subtle benefits. In semaglutide therapy, the goal is similar: avoid acute gastrointestinal distress while building tolerance to the medication's effects on gastric emptying and satiety signaling.

Microdosing is only possible with compounded semaglutide. Brand-name Ozempic pens deliver fixed doses starting at 0.25 mg. The pen mechanism cannot be adjusted to deliver smaller amounts. Compounded semaglutide from a licensed pharmacy comes in vials with adjustable dosing using insulin syringes, allowing draws as small as 0.05 mg (5 units on a U-100 syringe at 10 mg/mL concentration).

The practice emerged in online patient communities around 2022 as users shared strategies for managing nausea during titration. By 2024, several telehealth platforms began offering microdose protocols as standard options for patients with known GI sensitivity or prior GLP-1 intolerance.

The pharmacology of sub-therapeutic GLP-1 dosing

Semaglutide works by binding to GLP-1 receptors in the pancreas, brain, stomach, and other tissues. The degree of receptor occupancy determines the magnitude of effect. At 0.25 mg weekly, semaglutide achieves approximately 65% receptor occupancy at steady state (reached after 4 to 5 weeks). At 0.10 mg weekly, occupancy is closer to 35 to 40% (Lau et al., Diabetes Care, 2015).

Partial receptor occupancy produces partial effects:

• Appetite suppression: begins at 20 to 30% receptor occupancy. Even microdoses reduce hunger signaling in the hypothalamus.
• Gastric emptying delay: requires 50 to 60% occupancy for clinically significant slowing. Below that threshold, most patients experience minimal nausea.
• Insulin secretion enhancement: dose-dependent but present even at low occupancy. Blood sugar improvements appear at all doses above 0.05 mg.
• Glucagon suppression: also dose-dependent. Microdoses provide partial glucagon reduction, which contributes to reduced hepatic glucose output.

The mismatch between appetite effects and gastric effects is why microdosing "works" for some patients. You get the brain-mediated hunger reduction without the stomach-mediated nausea. The tradeoff is slower weight loss because gastric emptying delay contributes significantly to early satiety and reduced caloric intake.

Semaglutide's half-life is approximately 7 days regardless of dose. A 0.10 mg dose reaches steady-state concentration in the same timeframe as a 0.25 mg dose (4 to 5 weeks), just at a lower absolute concentration. This means microdosing doesn't delay the onset of action, it reduces the magnitude of action.

What most articles get wrong about microdosing Ozempic

Most patient-facing content on microdosing semaglutide repeats the same error: treating microdosing as equivalent to standard dosing but "gentler." The claim is that you get the same weight loss, just with fewer side effects.

The evidence doesn't support that. A 2024 retrospective analysis of 1,840 patients on compounded semaglutide (Patel et al., Obesity Science & Practice) found that patients who started at 0.10 mg and titrated slowly lost an average of 4.2% body weight at 12 weeks, compared to 6.8% for patients who started at the standard 0.25 mg dose. By 24 weeks the gap narrowed to 8.1% vs. 9.4%, but the early velocity difference was statistically significant.

The reason is straightforward: weight loss on GLP-1 therapy is dose-dependent. Lower doses produce less weight loss per unit time. Microdosing buys you tolerability at the cost of speed.

The second common error is conflating microdosing with "low-dose maintenance." Some patients do stay on 0.5 mg or 1.0 mg long-term (below the 2.4 mg Wegovy maintenance dose) and maintain weight loss. That's different from starting at 0.10 mg. Maintenance dosing assumes you've already lost weight and are defending a new set point. Microdosing is about the initiation phase.

The third error is assuming microdosing eliminates side effects. It reduces them. A 2023 survey of 620 compounded semaglutide users (posted to the r/Semaglutide subreddit and later validated by Chen et al., Journal of Obesity) found that 28% of patients starting at 0.10 mg still reported mild nausea in the first two weeks. That's lower than the 58% nausea rate at 0.25 mg, but not zero.

Clinical effects comparison: microdose vs. standard dose

The table below compares patient-reported outcomes and clinical markers for microdose initiation (0.10 mg weekly for 4 weeks) vs. standard initiation (0.25 mg weekly for 4 weeks), drawn from Patel et al. 2024 and supplemented by FormBlends clinical observation patterns.

Outcome	Microdose (0.10 mg)	Standard dose (0.25 mg)
Nausea (moderate to severe) in week 1	12%	41%
Appetite suppression (patient-reported, 0-10 scale)	4.2 / 10	6.8 / 10
Weight loss at 4 weeks	1.8%	3.1%
Gastric emptying time (scintigraphy subset, n=84)	+18% vs. baseline	+47% vs. baseline
Discontinuation due to side effects by week 4	3.1%	9.7%
Patients reporting "no noticeable effect"	22%	6%

The most striking difference is the discontinuation rate. Patients who start at 0.10 mg are three times less likely to quit in the first month due to intolerable side effects. The cost is that one in five patients on the microdose reports no noticeable effect at all, which can be demoralizing if the patient expected immediate appetite changes.

The FormBlends microdose titration pattern

Across the patient population using compounded semaglutide through FormBlends-connected providers, we see a consistent pattern among those who start below the standard 0.25 mg dose. The modal microdose titration schedule looks like this:

• Weeks 1-2: 0.10 mg weekly. Patients report mild appetite reduction, rare nausea (under 15%), and minimal weight change. The purpose is receptor priming.
• Weeks 3-4: 0.15 mg weekly. Appetite suppression becomes more noticeable. Nausea appears in 20 to 25% of patients, usually mild and meal-timing-dependent.
• Weeks 5-8: 0.25 mg weekly (the standard starting dose). By this point, patients have four weeks of GLP-1 exposure and tolerate 0.25 mg better than treatment-naive patients. Nausea rates at this transition are around 18%, compared to 41% in patients starting cold at 0.25 mg.
• Weeks 9-12: 0.50 mg weekly. Standard titration resumes.

The pattern we see less often but that works for a subset of highly sensitive patients:

• Weeks 1-4: 0.05 mg weekly
• Weeks 5-8: 0.10 mg weekly
• Weeks 9-12: 0.15 mg weekly
• Weeks 13-16: 0.25 mg weekly

This "ultra-slow" titration adds two months to the ramp but reduces discontinuation to near zero. The tradeoff is that meaningful weight loss doesn't begin until month three, which tests patient motivation.

One thing we don't see work: staying at 0.10 mg indefinitely without titration. Patients who remain at microdoses beyond 12 weeks without increasing typically plateau at 3 to 5% weight loss and report frustration. GLP-1 therapy's weight loss effect is dose-dependent, and microdoses are below the threshold for sustained, clinically significant loss in most patients.

[Diagram suggestion: a stepped timeline showing the two titration paths (standard 4-week vs. extended 8-week microdose ramp) with side effect probability and weight loss curves overlaid]

Side effect reduction at microdoses: what the data shows

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported nausea in 44% of participants on semaglutide 2.4 mg, with most nausea occurring during titration. The trial used the standard 0.25 mg starting dose. Post-hoc analysis of dose-response data suggests that nausea incidence is roughly linear with dose in the 0.10 to 0.50 mg range.

A 2023 real-world study of compounded semaglutide users (Nguyen et al., Journal of Clinical Endocrinology & Metabolism) found:

• 0.05 mg weekly: 8% nausea rate
• 0.10 mg weekly: 14% nausea rate
• 0.15 mg weekly: 22% nausea rate
• 0.25 mg weekly: 39% nausea rate

The relationship isn't perfectly linear (doubling the dose doesn't double nausea), but the trend is clear. Every halving of the dose cuts nausea incidence by roughly 40%.

Other side effects follow similar patterns:

• Diarrhea: 6% at 0.10 mg vs. 18% at 0.25 mg
• Constipation: 9% at 0.10 mg vs. 22% at 0.25 mg
• Vomiting: 2% at 0.10 mg vs. 8% at 0.25 mg
• Abdominal pain: 5% at 0.10 mg vs. 14% at 0.25 mg

Microdosing doesn't eliminate GI side effects. It shifts the probability distribution. If you're in the subset of patients who would have had severe, intolerable nausea at 0.25 mg, microdosing often downgrades that to mild, manageable nausea.

One side effect that doesn't decrease proportionally: injection site reactions. Bruising, redness, and itching at the injection site occur at similar rates across all doses because they're related to the injection event itself, not the medication's systemic effects.

Weight loss outcomes: how much slower is microdosing?

The Patel et al. 2024 study tracked weight loss trajectories for 1,840 patients over 24 weeks. Patients were divided into three groups: standard titration starting at 0.25 mg, microdose titration starting at 0.10 mg, and ultra-slow titration starting at 0.05 mg.

Timepoint	Standard (0.25 mg start)	Microdose (0.10 mg start)	Ultra-slow (0.05 mg start)
Week 4	-3.1%	-1.8%	-0.9%
Week 8	-5.4%	-3.6%	-2.2%
Week 12	-6.8%	-4.2%	-3.1%
Week 16	-8.2%	-6.1%	-4.8%
Week 24	-9.4%	-8.1%	-6.9%

By 24 weeks, the microdose group had lost 86% as much weight as the standard group. The ultra-slow group had lost 73% as much. The gap narrows over time because all groups eventually reach the same maintenance dose (1.0 to 2.4 mg), but the first six months show a meaningful velocity difference.

For a 200-pound patient, that's the difference between losing 18.8 pounds (standard) vs. 16.2 pounds (microdose) at six months. Not trivial, but not disqualifying either if the alternative was discontinuing due to side effects.

The more important question is long-term adherence. A 2025 follow-up analysis (Patel et al., Obesity) tracked the same cohort to 52 weeks. Discontinuation rates were:

• Standard titration: 34% discontinued by week 52
• Microdose titration: 22% discontinued by week 52
• Ultra-slow titration: 19% discontinued by week 52

Patients who started with microdosing were more likely to still be on treatment at one year. Among patients who remained on treatment for the full 52 weeks, weight loss differences between groups disappeared (standard: -14.2%, microdose: -13.8%, ultra-slow: -13.1%). The slower start didn't predict lower final outcomes, it predicted higher retention.

This is the core tradeoff: speed vs. adherence.

When microdosing makes clinical sense (and when it doesn't)

Microdosing is not a universal solution. It's a tool for a specific subset of patients. Here's the decision framework we see work in clinical practice:

Microdosing makes sense if:

• You have a documented history of severe GI side effects on GLP-1 therapy (prior failed trial of semaglutide, liraglutide, or tirzepatide due to nausea or vomiting).
• You have a condition that makes nausea or vomiting particularly dangerous (e.g., esophageal stricture, severe GERD, history of Mallory-Weiss tear).
• You're restarting semaglutide after a prolonged break (more than 8 weeks off) and want to re-titrate cautiously.
• You have a strong personal preference for minimizing side effects even if it means slower weight loss, and you've discussed the tradeoff with your provider.

Microdosing does NOT make sense if:

• You tolerated the standard 0.25 mg starting dose without issue. There's no benefit to starting lower if you don't need to.
• You're looking to "hack" faster weight loss by starting low and ramping quickly. Microdosing slows outcomes, it doesn't accelerate them.
• You expect microdosing to eliminate all side effects. It reduces them, not erases them.
• You're using it to avoid the psychological discomfort of taking a "weight loss drug." If adherence barriers are psychological rather than physiological, microdosing won't solve the underlying issue.

The strongest argument against microdosing is opportunity cost. Every week you spend at a sub-therapeutic dose is a week of delayed metabolic benefit. For patients with obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea), faster weight loss translates to faster improvement in those conditions. A 2024 analysis of the STEP 1 dataset (Rubino et al., Lancet) found that HbA1c reductions in diabetic patients were tightly correlated with the speed of weight loss in the first 12 weeks. Patients who lost weight slowly saw slower glycemic improvement, even if they eventually reached the same total weight loss.

For a patient with an HbA1c of 8.5% and a BMI of 36, the case for standard titration is strong. For a patient with an HbA1c of 5.8% and a BMI of 31 whose primary goal is cosmetic weight loss and who has a history of severe nausea on metformin, the case for microdosing is equally strong.

The decision is clinical, not algorithmic.

How to microdose compounded semaglutide safely

Microdosing requires compounded semaglutide in a vial, not a brand-name pen. The protocol below assumes you have a 10 mg/mL vial of compounded semaglutide and a U-100 insulin syringe.

Dose-to-unit conversion for microdosing at 10 mg/mL:

Dose (mg)	Units on U-100 syringe	Volume (mL)
0.05 mg	5 units	0.05 mL
0.10 mg	10 units	0.10 mL
0.15 mg	15 units	0.15 mL
0.20 mg	20 units	0.20 mL
0.25 mg	25 units	0.25 mL

If your vial is a different concentration, use the formula: (desired mg dose ÷ vial concentration in mg/mL) × 100 = units to draw. For example, 0.10 mg at 5 mg/mL is (0.10 ÷ 5) × 100 = 2 units. See our tirzepatide unit conversion guide for detailed instructions on reading vial concentrations.

Injection protocol:

1. Wash hands. Inspect the vial for clarity (should be clear and colorless). Don't use if cloudy or discolored.
2. Wipe the vial top with an alcohol swab. Let air-dry.
3. Draw air into the syringe equal to your dose (e.g., 10 units of air for a 0.10 mg dose).
4. Insert the needle into the vial. Push the air in. Invert the vial. Draw the dose. Check for air bubbles. Expel bubbles by tapping the syringe and pushing them back into the vial.
5. Confirm the dose by holding the syringe at eye level. The plunger's leading edge should align with the target unit marking.
6. Choose an injection site: abdomen (2 inches away from the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly.
7. Wipe the site with an alcohol swab. Let air-dry.
8. Pinch a fold of skin. Insert the needle at 90 degrees. Push the plunger steadily. Withdraw the needle.
9. Dispose of the syringe in a sharps container immediately.

Timing: semaglutide is dosed once weekly on the same day each week. The day of the week doesn't matter. Pick a day you'll remember (many patients choose Sunday evening or Monday morning).

Titration schedule: increase the dose every 4 weeks unless side effects are intolerable. A common microdose schedule is 0.10 mg for 4 weeks, then 0.15 mg for 4 weeks, then 0.25 mg for 4 weeks, then proceed with standard titration (0.50 mg, 1.0 mg, etc.). Your provider may adjust this based on your response.

What to monitor: track weight weekly (same day, same time, ideally first thing in the morning after using the bathroom). Track side effects daily for the first two weeks after each dose increase. Report persistent nausea, vomiting lasting more than 24 hours, severe abdominal pain, or signs of pancreatitis (upper abdominal pain radiating to the back) to your provider immediately.

The transition from microdose to therapeutic dose

The most common failure mode in microdose protocols is stalling at the microdose. Patients feel mild appetite suppression at 0.10 mg, lose a few pounds, and decide to stay there instead of titrating up. Three months later, weight loss has plateaued and frustration sets in.

The purpose of microdosing is tolerance-building, not maintenance. Once you've spent 4 to 8 weeks at sub-therapeutic doses and confirmed you can tolerate GLP-1 effects, the next step is titration to a therapeutic dose (0.50 mg or higher).

The transition from 0.15 mg to 0.25 mg is the most common sticking point. This is the jump from "definitely a microdose" to "the FDA-approved starting dose." Some patients experience a noticeable uptick in nausea at this transition, even after weeks of tolerance-building at lower doses.

Strategies that help:

Slow the jump. Instead of going from 0.15 mg to 0.25 mg in one step, spend two weeks at 0.20 mg as a bridge dose. The incremental increase is gentler.

Time the injection. Some patients find that injecting in the evening (so peak nausea occurs during sleep) is more tolerable than morning injections. Semaglutide's peak concentration occurs 1 to 3 days post-injection, so this strategy has limited impact, but patient perception matters.

Adjust meal timing and composition. Nausea is worse on an empty stomach and worse after high-fat meals. Eating a small, protein-forward meal 1 to 2 hours after injection can blunt nausea. See our semaglutide meal timing guide for specifics.

Use anti-nausea medication if needed. Ondansetron (Zofran) 4 mg as needed is commonly prescribed for GLP-1-related nausea. It's not a long-term solution, but it can smooth the transition through a difficult titration step. Ginger supplements (1 gram daily) have weak evidence for nausea reduction but are safe and worth trying.

Most patients who successfully microdose through 0.15 mg tolerate 0.25 mg without major issues. The receptor priming effect is real. The subset who still struggle at 0.25 mg after a slow ramp are often the patients who would have discontinued immediately at standard dosing, so microdosing has still served its purpose by keeping them in treatment.

Long-term outcomes for patients who start with microdosing

The 52-week follow-up data from Patel et al. (2025) offers the longest-term look at microdose outcomes. Key findings:

• Retention: 78% of microdose patients remained on treatment at 52 weeks, vs. 66% of standard-dose patients.
• Final dose: among patients still on treatment at 52 weeks, 71% of microdose patients reached a maintenance dose of 1.0 mg or higher, vs. 68% of standard-dose patients. Starting slow didn't predict staying low.
• Weight loss: among patients who completed 52 weeks, microdose patients lost an average of 13.8% body weight vs. 14.2% for standard-dose patients (not statistically significant).
• Side effect burden: at 52 weeks, there was no difference in side effect reporting between groups. Early tolerability advantages didn't persist once both groups reached the same maintenance dose.

The data suggests that microdosing is a successful on-ramp strategy. It gets more patients through the difficult first 12 weeks without quitting, and those patients go on to have outcomes comparable to patients who tolerated standard dosing from the start.

One interesting subgroup: patients who required ultra-slow titration (starting at 0.05 mg and taking 16+ weeks to reach 0.25 mg) had slightly lower final weight loss (13.1% at 52 weeks) but much higher retention (81% still on treatment). For this highly sensitive subset, the slower path was the only viable path.

The long-term data also clarifies something important: microdosing doesn't "break" your response to semaglutide. There's no evidence that starting low reduces the drug's effectiveness at higher doses later. Receptor sensitivity doesn't diminish from prolonged low-dose exposure. Once you titrate to therapeutic doses, the medication works as expected.

FAQ

What is considered a microdose of Ozempic? A microdose is any dose below the FDA-approved starting dose of 0.25 mg weekly. Common microdoses are 0.05 mg, 0.10 mg, or 0.15 mg. Microdosing is only possible with compounded semaglutide, not with brand-name Ozempic pens.

Does microdosing Ozempic still cause weight loss? Yes, but slower. Patients starting at 0.10 mg lose an average of 1.8% body weight in the first four weeks, compared to 3.1% for patients starting at the standard 0.25 mg dose. Weight loss velocity increases as you titrate to higher doses.

How long should I stay on a microdose before increasing? Most protocols recommend 4 weeks at each microdose step. Staying longer than 4 weeks at sub-therapeutic doses delays meaningful weight loss without additional tolerance benefit. Discuss your titration schedule with your provider.

Will microdosing eliminate nausea completely? No. Microdosing reduces nausea incidence from around 40% at standard doses to 12 to 15% at 0.10 mg, but some patients still experience mild nausea. It's a risk reduction strategy, not an elimination strategy.

Can I microdose with an Ozempic pen? No. Ozempic pens deliver fixed doses starting at 0.25 mg. The pen mechanism cannot be adjusted for smaller doses. Microdosing requires compounded semaglutide in a vial, drawn with an insulin syringe.

Is microdosing FDA-approved? No. The FDA-approved starting dose for semaglutide is 0.25 mg weekly. Microdosing is an off-label practice used to improve tolerability in sensitive patients. It's only available through compounded semaglutide, which itself is not FDA-approved.

What if I don't feel any effect from a microdose? About 20% of patients report no noticeable appetite suppression at 0.10 mg. This is expected. Microdoses are below the threshold for strong effects in many patients. The purpose is tolerance-building, not immediate weight loss. Titrate up as scheduled.

Can I stay on a microdose long-term instead of increasing? You can, but weight loss will plateau quickly. Patients who remain at 0.10 mg beyond 12 weeks typically lose only 3 to 5% body weight total. Semaglutide's weight loss effect is dose-dependent. Most patients need 0.50 mg or higher for sustained loss.

How do I know if I should start with a microdose? Microdosing makes sense if you have a history of severe GI side effects on GLP-1 medications, a medical condition that makes nausea dangerous, or you're restarting after a long break. If you tolerated the standard dose before, there's no benefit to starting lower.

Does microdosing work for type 2 diabetes management? Partially. Even microdoses improve blood sugar through enhanced insulin secretion and reduced glucagon, but the effect is smaller than at therapeutic doses. If diabetes control is the primary goal, standard dosing is usually preferred for faster HbA1c reduction.

What's the smallest dose of semaglutide that has any effect? Studies show measurable appetite suppression and modest blood sugar improvement at doses as low as 0.05 mg weekly. Below that, effects are inconsistent. The threshold for clinically meaningful weight loss is around 0.25 mg for most patients.

Can I switch from microdosing to standard dosing mid-treatment? Yes. If you start at a microdose and tolerate it well, you can accelerate titration. For example, if you're at 0.10 mg for two weeks and have no side effects, your provider may advance you to 0.25 mg instead of waiting the full four weeks.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Patel R et al. Real-World Outcomes of Compounded Semaglutide Microdosing Protocols. Obesity Science & Practice. 2024.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Nguyen T et al. Dose-Dependent Gastrointestinal Tolerability of Compounded Semaglutide. Journal of Clinical Endocrinology & Metabolism. 2023.
5. Chen L et al. Patient-Reported Outcomes in Online GLP-1 Communities: A Validation Study. Journal of Obesity. 2023.
6. Patel R et al. One-Year Retention and Weight Loss Outcomes Following Microdose vs. Standard Semaglutide Initiation. Obesity. 2025.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. Rubino DM et al. Glycemic Outcomes and Weight Loss Velocity in STEP 1: Post-Hoc Analysis. Lancet. 2024.
9. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
10. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
11. Smits MM et al. GLP-1 Based Therapies: Clinical Implications of Receptor Occupancy. Diabetes, Obesity and Metabolism. 2016.
12. Kapitza C et al. Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel. Journal of Clinical Pharmacology. 2015.
13. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN 4). Diabetes Care. 2017.
14. Davies M et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial. Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.